Trial Profile
The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Paricalcitol (Primary) ; Paricalcitol (Primary) ; Alfacalcidol; Cinacalcet; Doxercalciferol
- Indications Hyperparathyroidism
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms IMPACT SHPT
- Sponsors Abbott Laboratories; AbbVie
- 09 Apr 2014 Integrated data from the European Clinical Trials Database record.
- 09 Apr 2014 Integrated data from the ClinicalTrials.gov record.
- 09 Apr 2014 New trial record